Aimmune Therapeutics, Inc.

Company: Aimmune Therapeutics, Inc.

Deadline: TBD

Kaskela Law LLC is investigating Aimmune Therapeutics, Inc. (“Aimmune”) (NASDAQ: AIMT) on behalf of the company’s shareholders.

On August 31, 2020, Aimmune announced that it had entered into an agreement to be acquired by Sociétés des Produits Nestlé, S.A. (“Nestle”) for $34.50 per share in an all-cash transaction.

The firm’s investigation seeks to determine whether Aimmune’s directors breached their fiduciary duties in agreeing to sell the company to Nestle, and whether the proposed transaction as structured undervalues Aimmune’s common stock.

Aimmune shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by completing the information form on this page, for additional information about this investigation and their legal rights and options.

Kaskela Law represents current and former shareholders of publicly traded corporations in securities fraud class actions, shareholder derivative actions, and merger & acquisition litigation. The firm exclusively litigates cases on behalf of investors on a contingency basis – advancing all costs and fees until the successful resolution of a case.

Submit Your Information

  • Date Format: MM slash DD slash YYYY
  • This field is for validation purposes and should be left unchanged.